Certara is the global leader in accelerating medicines with biosimulation and tech-enabled services. Since 2014, their customers have received an impressive 90% of new drug approvals by the FDA, thanks to their cutting-edge software and services. Certara offers a wide range of software solutions, including their flagship products such as Phoenix PK/PD Platform, Phoenix WinNonlin™, and Phoenix NLME™, which are industry gold-standard tools for pharmacokinetic/pharmacodynamic analysis and in vitro-in vivo correlation studies.

They also provide Simcyp™ PBPK Simulator, a versatile tool for translational modeling and simulation, and D360™ Scientific Informatics Software, which shortens the drug discovery cycle. Certara's services include model-informed drug development, biometrics and data sciences, drug development, regulatory services, medical communications, and safety and pharmacovigilance. Their expertise extends to specialty areas such as cell and gene therapy, pediatrics, oncology, rare disease and orphan drug development, and complex biologics.

With a commitment to social and environmental responsibility, Certara is dedicated to driving innovation and accelerating the delivery of safe and effective medicines